Literature DB >> 34847819

Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers.

Filippos Filippatos1, Elizabeth-Barbara Tatsi1, Charilaos Dellis1, Nick Dessypris2, Vassiliki Syriopoulou1, Athanasios Michos1.   

Abstract

INTRODUCTION: The aim of the study was to investigate the prevalence and severity of adverse reactions (ARs) after immunization of healthcare workers (HCWs) with BNT162b2 vaccine and to associate them with clinical and epidemiological characteristics.
METHODS: A form containing demographic and clinical data as well as ARs after both doses of the vaccine was completed, and statistical association analysis was performed.
RESULTS: A total of 502 HCWs (females 78.3%) with mean age (±SD) 48.17 years (±12.97) participated. After the first dose, 404 (80.5%) HCWs reported at least one local AR (LAR) and 366 (72.9%) after the second dose (p-value=0.004). After the first dose, 121 (24.1%) HCWs reported at least one systemic AR (SAR) and 275 (54.8%) after the second dose (p-value<0.0001).In the logistic regression analysis, there was no association of gender or medical history of underlying disease with LARs. There was a negative association of age with the cumulative score (CS) of LARs (OR: 0.82, 95% CI: 0.69-0.96) after the first dose. Females had a positive association with CS of SARs following both doses (OR, 95% CI: 2.57, 1.39-4.73 and 2.71, 1.76-4.19, respectively). Age was negatively associated with CS of SARs (OR: 0.66, 95% CI: 0.57-0.76) after the second dose. Severe ARs included Bell's palsy (1) and tinnitus with temporary hearing loss (1).
CONCLUSION: The administration of the BNT162b2 vaccine in our HCWs cohort had a good safety profile with the most common ARs being self-limited. An increasing rate of SARs following the second vaccine dose was noticed. Rare but severe possible ARs should be further investigated.

Entities:  

Keywords:  Healthcare worker; adverse reactions; biontech; mRNA; vaccine

Mesh:

Substances:

Year:  2021        PMID: 34847819      PMCID: PMC8904023          DOI: 10.1080/21645515.2021.1985356

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  23 in total

1.  The lightning-fast quest for COVID vaccines - and what it means for other diseases.

Authors:  Philip Ball
Journal:  Nature       Date:  2020-12-18       Impact factor: 49.962

2.  Association Between ABO and Rh Blood Groups and SARS-CoV-2 Infection or Severe COVID-19 Illness : A Population-Based Cohort Study.

Authors:  Joel G Ray; Michael J Schull; Marian J Vermeulen; Alison L Park
Journal:  Ann Intern Med       Date:  2020-11-24       Impact factor: 25.391

3.  Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.

Authors:  Si Ho Kim; Yu Mi Wi; Su Yeon Yun; Jeong Seon Ryu; Jung Min Shin; Eun Hui Lee; Kyung Hwa Seo; Sung Hee Lee; Kyong Ran Peck
Journal:  J Korean Med Sci       Date:  2021-04-12       Impact factor: 2.153

4.  Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.

Authors:  Evangelos Terpos; Ioannis P Trougakos; Filia Apostolakou; Ioanna Charitaki; Aimilia D Sklirou; Nefeli Mavrianou; Eleni-Dimitra Papanagnou; Christine-Ivy Liacos; Sentiljana Gumeni; Gianna Rentziou; Eleni Korompoki; Ioannis Papassotiriou; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2021-04-10       Impact factor: 10.047

5.  First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.

Authors:  Julianne Gee; Paige Marquez; John Su; Geoffrey M Calvert; Ruiling Liu; Tanya Myers; Narayan Nair; Stacey Martin; Thomas Clark; Lauri Markowitz; Nicole Lindsey; Bicheng Zhang; Charles Licata; Amelia Jazwa; Mark Sotir; Tom Shimabukuro
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-02-26       Impact factor: 17.586

6.  Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.

Authors:  Tom Shimabukuro; Narayan Nair
Journal:  JAMA       Date:  2021-02-23       Impact factor: 56.272

7.  Tinnitus following COVID-19 vaccination: report of three cases.

Authors:  Daniela Parrino; Andrea Frosolini; Chiara Gallo; Romolo Daniele De Siati; Giacomo Spinato; Cosimo de Filippis
Journal:  Int J Audiol       Date:  2021-06-13       Impact factor: 2.437

8.  Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.

Authors:  Jay Montgomery; Margaret Ryan; Renata Engler; Donna Hoffman; Bruce McClenathan; Limone Collins; David Loran; David Hrncir; Kelsie Herring; Michael Platzer; Nehkonti Adams; Aliye Sanou; Leslie T Cooper
Journal:  JAMA Cardiol       Date:  2021-10-01       Impact factor: 30.154

9.  Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncologic Patients.

Authors:  Can Özütemiz; Luke A Krystosek; An L Church; Anil Chauhan; Jutta M Ellermann; Evidio Domingo-Musibay; Daniel Steinberger
Journal:  Radiology       Date:  2021-02-24       Impact factor: 11.105

10.  Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.

Authors:  Cristina Menni; Kerstin Klaser; Anna May; Lorenzo Polidori; Joan Capdevila; Panayiotis Louca; Carole H Sudre; Long H Nguyen; David A Drew; Jordi Merino; Christina Hu; Somesh Selvachandran; Michela Antonelli; Benjamin Murray; Liane S Canas; Erika Molteni; Mark S Graham; Marc Modat; Amit D Joshi; Massimo Mangino; Alexander Hammers; Anna L Goodman; Andrew T Chan; Jonathan Wolf; Claire J Steves; Ana M Valdes; Sebastien Ourselin; Tim D Spector
Journal:  Lancet Infect Dis       Date:  2021-04-27       Impact factor: 25.071

View more
  1 in total

1.  Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System.

Authors:  Congqin Chen; Fang Fu; Lingqing Ding; Jie Xiao
Journal:  J Clin Pharm Ther       Date:  2022-09-11       Impact factor: 2.145

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.